COPART, INC. Form 8-K Summary
Business Context and Reporting Period
Date of Report: September 10, 2026
Company: COPART, INC. (Parent)
Subject: Entry into a Material Definitive Agreement to acquire ACV Auctions Inc. (ACV).
Transaction Type: Cash tender offer followed by a merger.
Key Financial Metrics and Transaction Terms
This filing details a proposed acquisition rather than reporting periodic financial results (revenue, profit, or cash flow) for COPART or ACV. Key financial terms of the transaction include:
- Offer Price: $10.50 per share of ACV common stock in cash.
- Termination Fee (ACV to Parent): $57,700,000 payable if ACV terminates to accept a Superior Proposal.
- Termination Fee (Parent to ACV): $115,300,000 payable under specific circumstances, including regulatory injunctions or failure to satisfy HSR conditions.
- Support Agreement: Holders of approximately 4.1% of ACV stock have agreed to tender shares and vote in favor of the merger.
Material Changes and Transaction Structure
The filing announces a definitive agreement to acquire ACV Auctions Inc. The transaction structure involves:
- Two-Step Process: A cash tender offer for all outstanding ACV shares, followed by a merger of a subsidiary (Apple Merger Sub, Inc.) into ACV.
- Minimum Condition: The offer is contingent on receiving tenders representing more than 50% of outstanding ACV shares (plus one share).
- Financing: The consummation of the offer is not subject to any financing condition.
- Equity Treatment:
- Vested Options: In-the-money options will be cashed out; out-of-the-money options will be canceled for no consideration.
- Unvested Options/RSUs: Will generally convert to COPART equity awards based on an Exchange Ratio.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook: The filing references an investor presentation (Exhibit 99.2) regarding anticipated benefits, cost and revenue synergies, and the expected impact on COPART's revenue growth and earnings per share. However, specific numerical guidance is not provided in this text.
Risks and Contingencies: The transaction is subject to customary closing conditions, including:
- Expiration of the Hart-Scott-Rodino (HSR) Antitrust waiting period.
- Absence of court injunctions prohibiting the merger.
- Receipt of required regulatory approvals.
- Integration risks regarding ACV's business, operations, and technology.
- Potential stockholder litigation.
Forward-Looking Statements: The document contains forward-looking statements regarding the timing of the tender offer, the realization of synergies, and the combined company's growth profile. Actual results may differ materially due to the risks outlined above.
Investor Verification Checklist
- Verify the final tender offer materials (Schedule TO) and ACV's recommendation statement (Schedule 14D-9) once filed with the SEC.
- Confirm the exact Exchange Ratio for converting ACV equity awards to COPART equity, as this is defined in the full Merger Agreement.
- Monitor regulatory approval status, specifically regarding the HSR Act and competition laws.
- Review the full text of the Merger Agreement (Exhibit 2.1) for detailed representations, warranties, and termination rights.
- Assess the impact of the $115.3 million reverse termination fee on COPART's liquidity if regulatory approval is denied.